2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 201–300 of 2,029
Zhou, Y., Boucsein, A., Michaels, V. R., Gray, M. K., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16210 · Cited by 11
Syed, R. U., Moni, S. S., Hussein, W., Alhaidan, T. M. S., Abumilha, S. M. Y., Alnahdi, L. K., Wong, L. S., Subramaniyan, V., & Kumarasamy, V. (2025) · Scientific Reports · doi:10.1038/s41598-025-87319-7 · Cited by 16
Associations of carbohydrate quality and cardiovascular risk factors vary among diabetes subtypes
Weber, K. S., Schlesinger, S., Goletzke, J., Straßburger, K., Zaharia, O., Trenkamp, S., Wagner, R. J., Lieb, W., Buyken, A. E., Roden, M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02580-4 · Cited by 12
Risi, R., Amendolara, R., Pantano, A. L., Fassino, V., D’Onofrio, L., Coraggio, L., Luverà, D., Masi, D., Watanabe, M., Gnessi, L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02635-6 · Cited by 10
“Type 2 diabetes (T2D), the most frequent form of diabetes, results from a relative defect of insulin secretion on the background of insulin-resistance [1].”
Guo, D., Li, T., Yang, Q., Yang, C., Yang, Y., Liu, F., Ma, J., Tu, J., Ning, X., Wang, J., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1522989 · Cited by 10
STROEBEL, B. M., Gadgil, M. D., Lewis, K., Longoria, K. D., Zhang, L., & Flowers, E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf163 · Cited by 9
Exploring Saliva as a Sample for Non-Invasive Glycemic Monitoring in Diabetes: A Scoping Review
Calixto, P. S., Ferraz, F. C., Dutra, G. C., Pelozzo, M. J. B., Trovão, M. E., Rego, F. G. D. M., Picheth, G., Campelo, P. M. S., & Sari, M. H. M. (2025) · Biomedicines · doi:10.3390/biomedicines13030713 · Cited by 14
“Traditionally, diabetes is diagnosed and monitored through a combination of laboratory tests, physical examinations, and evaluations of medical history [6].”
Muntean, M., Săsăran, V., Luca, S.-T., Suciu, L. M., Nyulas, V. A., Elena, M. I., & Claudiu, M. (2024) · Medicina · doi:10.3390/medicina60091544 · Cited by 14
“GDM is diabetes diagnosed in the second or third trimester of pregnancy that was not diagnosed as overt diabetes before gestation [11].”
BackgroundYang, H.-X., Hu, Y., Liang, R., et al. (2025) · Cells · doi:10.3390/cells14151173 · Cited by 9
“It is estimated that type 2 diabetes accounts for 90–95% of all cases of diabetes [57].”
Guo, M., Fang, Y., Peng, M., He, C., Chen, J., Sun, B., Liu, C., Zhou, Y., Zhang, H., & Zhao, K. (2024) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2024.114419 · Cited by 12
Peralta, F. G., Pinés-Corrales, P. J., Santos, E., Cuesta, M., Albarrán, O. G., Azriel, S., & on behalf the AGORA Diabetes Collaborative Group (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164839 · Cited by 14
Zhao, L., Kang, S., & Kang, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-71904-3 · Cited by 12
“Diabetes was defined as the occurrence of any of the following conditions: fasting glucose level of ≥ 126 mg/dL, HbA1C level of ≥ 6.5%, physician-diagnosed diabetes, injecting insulin, or intake of antidiabetic pills to lower blood sugar 18 .”
BackgroundInfluentialPhillips, N. E., Mareschal, J., Biancolin, A. D., Sinturel, F., Umwali, S., Blanc, S., Hemmer, A., Naef, F., Salathé, M., Dibner, C., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06318-x · Cited by 12
PREVALENCE, Characteristics, and Awareness of Chronic Kidney Disease in Croatia: The EH-UH 2 Study
Jelaković, A., Radunović, D., Josipović, J., Vrkić, T. Ž., Gellineo, L., Domislovic, M., Prelević, V., Živko, M., Fuček, M., Glavić, M. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226827 · Cited by 12
“Diabetes was defined as fasting blood glucose > 7 mmol/L and/or taking antidiabetic drugs [35].”
Zhang, M., Coppell, K. J., Lo, J., & Whitehead, L. (2024) · Journal of Advanced Nursing · doi:10.1111/jan.16621 · Cited by 12
Muscogiuri, G., Caporusso, M., Caruso, P., Poggi, C. D., Vitale, M., Zurru, A., Colao, A., & the Italian Study Group on Gender Difference in Endocrine Diseases (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02491-3 · Cited by 13
“Changes in modifiable cardiometabolic risk factors may lead to a reduction or a delay in the onset of diabetes [ 9 , 10, 13.”
InfluentialOstrominski, J. W., Lassen, M. C. H., Claggett, B. L., Miao, Z. M., Inzucchi, S. E., Docherty, K. F., Desai, A. S., Jhund, P. S., Køber, L., Ponikowski, P. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae780 · Cited by 13
Mourelatou, N. G., Kounatidis, D. C., Jude, E. B., & Rebelos, E. (2024) · Nutrients · doi:10.3390/nu16234072 · Cited by 13
Integrated Analysis of Oral Microbiome and Metabolome in T2DM Patients With Varying Glycemic Status
Diao, J., Zhang, Y., Zhang, X., Jia, S., Lei, Y., Ma, B., Li, X., Zheng, S., & Yuan, C. (2024) · Oral Diseases · doi:10.1111/odi.15220 · Cited by 12
“We enrolled 42 T2DM patients with periodontitis and categorized them into three groups on account of HbA1c levels and ADA standards.”
InfluentialCacciatore, S., Calvani, R., Mancini, J., Ciciarello, F., Galluzzo, V., Tosato, M., Marzetti, E., & Landi, F. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112666 · Cited by 15
Deep learning-based automated tool for diagnosing diabetic peripheral neuropathy
Qiao, Q., Cao, J., Xue, W., Qian, J., Wang, C., Pan, Q., Lu, B., Xiong, Q., Chen, L., & Hou, X. (2024) · Digital Health · doi:10.1177/20552076241307573 · Cited by 14
New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences
Popović, L., & Bulum, T. (2025) · Diagnostics · doi:10.3390/diagnostics15030284 · Cited by 17
“However, HbA1c becomes reliable for diagnosing and monitoring NODAT beyond three months post-transplant, once blood counts normalize [15–19].”
Wentworth, J. M., Sing, A. B. E., Naselli, G., Huang, D., Azidis-Yates, E., Mandlebe, B., Brown, J. D., McGorm, K. J., Hall, C., Redl, L., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2443 · Cited by 14
Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6‐year prospective study
Liu, D., Yu, S., Zhang, Y., Li, Q., Kang, P., Wang, L., Han, R., Cheng, D., Chen, A., Hou, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16224 · Cited by 17
Lipodystrophy Severity Score to Assess Disease Burden in Lipodystrophy
Brown, R. J., Akıncı, B., Yosef, M., Phillips, H., Khalatbari, S. H., Sorkina, E., Santini, F., Vigouroux, C., Brush, M. N., Meral, R., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf103 · Cited by 11
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi, A., Weiss, L., Besançon, A., Stremler, N., Reix, P., Wizla, N., Lustre, A., Rames, C., Tatopoulos, A., Périsson, C., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf099 · Cited by 9
Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
Galderisi, A., Bonet, J., Ismail, H. M., Moran, A., Fiorina, P., Bosi, E., & Petrelli, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf086 · Cited by 9
Tsokkou, S., Tzintros, S.-T., Konstantinidis, I. K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051646 · Cited by 9
“The current classification distinguishes between Type 1 (T1DM); Type 2 (T2DM); specific types of diabetes as a result of other causes, e.g., monogenic diabetes syndrome, drug-or chemical-induced diabetes, and diseases of the exocrine pancreas; and gestational diabetes mellitus (GDM) [6,7].”
Wang, A., Östgren, C. J., Norhammar, A., Kylhammar, D., Jernberg, T., Lind, L., Söderberg, S., Blomberg, A., Engström, G., Bergström, G. M. L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02634-7 · Cited by 11
“As a secondary exposure, dysglycemia defined according to the American Diabetes Association’s (ADA) classification was used with a difference in definitions of normoglycemia (glucose 5.6 mmol/L and HbA1c 39 mmol/mol) and prediabetes (IFG 5.6–6.9 mmol/L or elevated HbA1c 39–47 mmol/mol) [16].”
InfluentialLian, H., Ren, Q., Liu, W., Zhang, R., Zou, X., Zhang, S., Luo, Y., Deng, W., Wang, Q., Lin, Q., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02665-0 · Cited by 12
Chen, C., Gao, H., Wei, Y., & Wang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1511701 · Cited by 11
“Some researchers describe T1DM as a “ chronic anti-auto-in fl ammatory response, ” and there is a theory suggesting that pancreatic in fl ammation may be the most important cause of T1DM (Committee, 2024; Gearty et al., 2022).”
Tang, Y., Chen, Y., Zhou, Y., Wu, B., Zhang, S., Gong, Y., & Ni, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1557923 · Cited by 17
Li, C., Gong, H., Shi, P., Liu, S., & Zhang, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094417 · Cited by 10
Metabolite 2-aminoadipic acid: implications for metabolic disorders and therapeutic opportunities
Shi, W., Yang, Z., Fu, P., & Yang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1569020 · Cited by 10
Díaz, Á. M. M., Lomas, S. B., Gómez, P. R. D. V., González, M. V. L., Rodríguez, C. M., Sotelo, L. H., & Brocca, M. A. M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1563410 · Cited by 14
“…internal patient registry, applying the following inclusion criteria: adults aged 18 years or older, con fi rmed diagnosis of T1D [ADA 2024 criteria (9)], at least one year of evolution since diagnosis of T1D, treatment with multiple daily insulin injections (MDI) or sensor-augmented insulin pump…”
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 12
“…with obesity (BMI ≥ 30), with a diagnosis of IGT or IFG or T2DM for less than 12 months, according to the American Diabetes Association (ADA) Guidelines [19], under diet therapy associated with ongoing metformin treat-ment at the highest tolerated dose (up to 3000 mg/day) at the time of enrolment.”
de Molon, R. S. (2025) · Dentistry Journal · doi:10.3390/dj13070309 · Cited by 11
“The condition is broadly classified into type 1 diabetes, which is caused by autoimmune destruction of pancreatic β -cells leading to absolute insulin deficiency, and type 2 diabetes, which involves insulin resistance combined with a relative insulin secretory defect [1].”
Non-autoimmune diabetes in young people from Assam, India: the PHENOEINDY-2 study
Dutta, A., Dutta, P. K., Baruah, S. M., Dihingia, P., Ray, A., Bhat, D., Patki, S. W., Tiwari, P., Deshmukh, M., Wagh, R. S. H., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06500-9 · Cited by 10
Call for Standardization of C-Peptide Measurement
Schleicher, E. D., Kabytaev, K., Nauck, M., Müller‐Wieland, D., Peter, A., Little, R. R., & Heinemann, L. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251362848 · Cited by 14
Sexual orientation, gender identity and cardiometabolic risk: a narrative review
Duncan, M. S., Beach, L. B., Wolfe, H. L., Restar, A., Rivera, A. S., & Streed, C. G. (2025) · Diabetologia · doi:10.1007/s00125-025-06572-7 · Cited by 11
Low-calorie diets for people with isolated impaired fasting glucose
Sathish, T., Taylor, R., Khunti, K., Tapp, R. J., Raben, A., Zhu, R., Kapoor, N., Narayan, K. M. V., Ali, M. K., & Shaw, J. E. (2024) · Communications Medicine · doi:10.1038/s43856-024-00466-2 · Cited by 10
Self-citationAn update on drug–drug interactions in older adults living with human immunodeficiency virus (HIV)
Linfield, R. Y., Nguyen, N. N., Laprade, O. H., Holodniy, M., & Chary, A. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2350968 · Cited by 14
“The American Diabetes Association (ADA) recommends screening all PWH for diabetes, with repeat testing in 3–6 months if the result is near the margin threshold; there is no separate HIV-specific guidance for diabetes management from the ADA [151].”
Zhao, L., Zeng, Q., Zhou, X., Tang, L., Wang, Y., Han, Q., Zou, Y., Xiao, X., Liu, K., Ju, X., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15758 · Cited by 10
Xie, C., Ren, Y., He, Q., Wang, C., & Luo, H. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1459062 · Cited by 10
Mogoş, R. A., Gheorghe, L., Cărăuleanu, A., Vasilache, I.-A., Munteanu, I.-V., Mogoş, S. J., Solomon-Condriuc, I. P., Băean, M.-L., Socolov, D. G., Adam, A.-M., et al. (2024) · Medicina · doi:10.3390/medicina60081298 · Cited by 15
“OR fasting plasma glucose (FPG) ≥ 126 mg/dL (7 mmol/L) OR a 2 h plasma glucose 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT) OR a random plasma glucose 200 mg/dL (11.1 mmol/L) in patients experiencing classic symptoms of hyperglycemia or hyperglycemic crisis [18].”
BackgroundInfluentialDesiderio, A., Pastorino, M., Campitelli, M., Prevenzano, I., Palma, F. D. E. D., Spinelli, R., Parrillo, L., Longo, M., Milone, M., Miele, C., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401470r · Cited by 10
Argyropoulou, D., Nomikos, T., Terzis, G. D., Tataki, S., Geladas, N. D., & Paschalis, V. (2025) · European Journal of Nutrition · doi:10.1007/s00394-024-03575-9 · Cited by 10
Yang, L., Xie, D., Liu, F., Lin, J., Lin, X. Y., Chen, Y., & Zhang, K. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70043 · Cited by 9
Hyperactivity and Pro-inflammatory Functions of Platelets in Diabetes
Greaves, J., & Pula, G. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26190 · Cited by 15
Azova, S., Laffel, L. M., Lennerz, B. S., Petty, C. R., Wolfsdorf, J. I., Rhodes, E. T., & Garvey, K. C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112041 · Cited by 9
“Ranges for both measurements are the same, and both methods are certified by the National Glycohemoglobin Standardization Program and performed under the requisite Clinical Laboratory Improvement Amendment standards as recommended by the ADA [32].”
Yan, C., Chen, G., Jing, Y., Qi, R., & Liu, P. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01638-3 · Cited by 11
“Diabetes is one of the chronic diseases with rapidly increasing incidence and prevalence worldwide [1], it not only affects glucose metabolism, but also triggers a variety of metabolic dysfunctions, which significantly increases the risk of cardiovascular disease [2].”
CEFALO, C. M. A., Riccio, A., Fiorentino, T. V., Succurro, E., Perticone, M., Cassano, V., Sciacqua, A., Andreozzi, F., & Sesti, G. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70013 · Cited by 9
Chen, Y.-R., Zhang, Y.-D., Qin, S., Yu, F.-D., Ni, Y.-X., & Zhong, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1525105 · Cited by 6
Adjei, S. K., Adjei, P., & Nkrumah, P. A. (2025) · Health Science Reports · doi:10.1002/hsr2.70558 · Cited by 11
Gao, M., Li, N., Wang, H., Li, W., Zhang, T., Qiao, Y., Li, J., Yu, Z., Hu, G., Leng, J., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112126 · Cited by 8
Neutrophils in Type 1 Diabetes: Untangling the Intricate Web of Pathways and Hypothesis
Nigi, L., Pedace, E. A., Sebastiani, G., & Dotta, F. (2025) · Biomolecules · doi:10.3390/biom15040505 · Cited by 8
“T1D is a chronic autoimmune condition characterized by the immune system’s targeted dysfunction and destruction of pancreatic β -cells, leading to insulin deficiency [17].”
HbA1c and the Risk of Lower Limb Ulcers Among Diabetic Patients: An Observational and Genetics Study
Guo, G., Guan, Y., Chen, Y., Ye, Y., Gan, Z., Cao, X., Chen, Z., & Hao, X. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/4744194 · Cited by 14
Jarullah, H. H., & Saleh, E. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094015 · Cited by 10
Impact of parity on gestational diabetes mellitus in Chinese women: a retrospective cohort study
Dai, Y., Wang, Y., Chen, M., Lin, Q., Situ, J., Yu, Y., & Meng, L. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07620-1 · Cited by 14
“GDM, recognized as one of the most common pregnancy complications [15], has been linked to parity in prior research; however, the results have been inconsistent.”
Regulation of pancreatic β cells by exosomes from different sources
Gao, Y., Chen, Q., Wu, Z., & Li, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112222 · Cited by 11
Stamate, E., Culea-Florescu, A.-L., Miron, M., Piraianu, A. I., Dumitrascu, A. G., Fulga, I., Fulga, A., Patrascanu, O. S., Iancu, D., Ciobotaru, O. C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103503 · Cited by 8
The Challenge of Type 3c Diabetes: From Accurate Diagnosis to Effective Treatment
Milani, I., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf109 · Cited by 12
Konantambigi, A., Wang, W., Boggild, D., Rana, A., Syphers, L., Presley, C., Cummins, C., Malabu, U. H., Hawke, K., Shenoy, V. V., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16485 · Cited by 9
“28 This is particularly relevant in populations with previously suboptimal control and may have long-term implications for reducing the burden of diabetes-related complications.”
Ichikawa, T., Okada, H., Hamaguchi, M., Hara, M., Takashima, N., Suzuki, S., Tanoue, S., Kato, Y., Nagayoshi, M., Tamura, T., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02634-2 · Cited by 7
“Dyslipidemia, hypertension, and diabetes were defined based on established clinical criteria, as detailed in Supplementary Table 3 [22–28].”
Grobman, B., Turkson‐Ocran, R., Zhang, M., & Juraschek, S. P. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101045 · Cited by 11
Molani‐Gol, R., Rafraf, M., & Safari, S. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00994-1 · Cited by 11
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 13
“Based on the nephroprotection data by RCTs, the American Diabetes Association’s 2024 Standards of Care recommended, for the management of patients with type 2 diabetes and CKD, that an SGLT2i with documented evidence of reduced CKD progression is preferred [102].”
Prinzi, A., Lombardo, A. M., Finocchiaro, S., Galvano, A., Vella, V., Frasca, F., & Malandrino, P. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.009 · Cited by 19
A digital twin of glimepiride for personalized and stratified diabetes treatment
Elias, M., & König, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1686415 · Cited by 9
Suleiman, M., Sawatani, T., Tesi, M., Yi, X., Papadopoulou, T. A., Rufer, C., Lytrivi, M., Bosi, E., Burdet, F., Fantuzzi, F., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads2905 · Cited by 18
“No β cell functional improvement was seen in islets cultured at 11.1 mM glucose, suggesting that glucose levels in people with T2D should be kept as close as possible to the physiological range to preserve/restore β cell function ( 53 ).”
InfluentialNguyen, H. H. K., Le, H. M., Thang, L. Q., Ngan, D. T. Q., Thoi, N. T., Phuong, N., Hoang, D. M., & Huynh, C. D. (2025) · iScience · doi:10.1016/j.isci.2025.114375 · Cited by 13
Tığlı, A., Baykuş, Y., Deniz, R., Selçuk, K. T., Şener, N., Değirmenci, Y. E., Akıncı, G. E., Acarturk, İ. Z., Sertdemir, N., & Aydın, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1765602 · Cited by 13
“According to current guidelines, the clinical diagnosis of GDM is made with a 75 g Oral Glucose Tolerance Test (OGTT) at 24–28 weeks of gestation (7–9).”
Santos‐Báez, L. S., Díaz‐Rizzolo, D. A., Popp, C. J., Shaw, D., Fine, K. S., Altomare, A., St‐Onge, M., Manoogian, E. N. C., Panda, S., Cheng, B., et al. (2024) · Nutrients · doi:10.3390/nu16091295 · Cited by 10
Mosleh, K. A., Ghusn, W., Salameh, Y., Jawhar, N., Hage, K., Mundi, M. S., Dayyeh, B. K. A., & Ghanem, O. M. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.07.018 · Cited by 8
Candido, R., Toffoli, B., Manfredi, G., Turisani, A., Delfauro, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., Travan, L., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02405-y · Cited by 10
“For instance, the 2024 American Diabetes Associa - tion (ADA) standards [2 ] recommend testing women before 15 weeks of gestation with fasting glucose and glycated hemoglobin to detect those who have diabetes and those who are more likely to develop late GDM (i.e. fasting glu - cose 110–125 mg/dL…”
InfluentialPolysaccharides: The Sweet and Bitter Impacts on Cardiovascular Risk
Kalisz, G., & Popiołek-Kalisz, J. (2025) · Polymers · doi:10.3390/polym17030405 · Cited by 10
“Diabetes mellitus is a group of metabolic disorders of carbohydrate metabolism, resulting in chronic hyperglycemia [71].”
Olfactory function in diabetes mellitus
Sienkiewicz-Oleszkiewicz, B., & Hummel, T. R. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100342 · Cited by 9
“Depending on the etiology, DM can be classified as type 1 (T1DM), type 2 (T2DM) (the most common), gestational and other specific, less common types [2].”
BackgroundHou, Q., & Yi, B. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3809 · Cited by 7
Qiu, S., Liu, X., Lei, L., Liang, H., Li, X., Wang, Y., Yu, C., Li, X., Tang, Y., Wu, J., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13567 · Cited by 6
“34 CKD was defined as incident eGFR less than 60 mL/min/1.73 m 2 .”
BackgroundInfluentialPresepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study
Kouroupis, D., Zografou, I., Balaska, A., Reklou, A., Varouktsi, A., Paschala, A., Pyrpasopoulou, A., Stavropoulos, K., Vogiatzis, K., Sarvani, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091960 · Cited by 7
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 12
Beretta, M. V., Flores, C., Colameo, G. F., Echabe, L. W., & Busnello, F. M. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae123 · Cited by 9
Liu, Z., Asuzu, P., Patel, A., Wan, J. Y., & Dagogo-Jack, S. E. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae202 · Cited by 12
Heybeli, C., Uzun, Ö., Smith, L., Veronese, N., Rahmati, M., Hajek, A., & Soysal, P. (2024) · Nutrition in Clinical Practice · doi:10.1002/ncp.11246 · Cited by 9
Reis, F. V. D. D. S., Filho, C. I. S., Sobrevía, L., Prudêncio, C. B., Bologna, B., Iamundo, L. F., Magyori, A. B. M., Takano, L., Avramidis, R. E., de Oliveira, R. G., et al. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00196-3 · Cited by 11
“The ADA recommends a well-established protocol for GDM screening between 24–28 weeks of gestation through a 75-g OTTG [1].”
InfluentialPrevalence and incidence of prediabetes in Latin America. A systematic review and meta-analysis
Vera-Ponce, V. J., Loayza-Castro, J. A., Zuzunaga-Montoya, F. E., Sanchez-Tamay, N. M., Bustamante-Rodríguez, J. C., Valladolid-Sandoval, L. A. M., Vásquez-Romero, L. E. M., & Carrillo, C. I. G. D. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01549-6 · Cited by 13
“According to the ADA crite - ria [ 9 ], prediabetes is diagnosed when fasting glucose levels are between 100 and 125 mg/dL (5.6–6.9 mmol/L), or when 2-hour postprandial glucose during a 75 g oral glucose toler - ance test (OGTT) ranges from 140 to 199 mg/dL (7.8–11.0 mmol/L), or when glycated…”
InfluentialKazé, A. D., Bertoni, A. G., Fox, E. R., Hall, M. E., Mentz, R. J., Berry, J. D., & Echouffo-Tcheugui, J. B. (2025) · Diabetes Care · doi:10.2337/dc24-0654 · Cited by 8
Hasan, M. A., Alismail, M. A., Bokhari, D., Alghamdi, R. F., Alhalal, Z. E., Alqatari, S. G., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61020181 · Cited by 7
“Diabetes mellitus (DM) was defined as hemoglobin A1C ≥ 6.5%, fasting blood glucose ≥ 126 mg/dL, or random blood glucose ≥ 200 mg/dl with symptoms [18].”
InfluentialLi, Y., Shan, L., Wen, Q., Cao, C., Huang, M., Zhang, C., Li, X., Wang, K., Zhou, T., Zha, F., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01834-2 · Cited by 9
“Participants with DM were those whose FPG was 7 mmol/l [17], whose HbA1c was not less than 6.5%, or who self-reported throughout the follow-up period.”
InfluentialAltered brain functional network connectivity and topology in type 2 diabetes mellitus
Ni, W., Liu, W. V., Li, M., Wei, S., Xu, X., Huang, S., Zhu, L., Wang, J., Wen, F., & Zhou, H. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1472010 · Cited by 11
Chang, Y., Huang, Y., Li, R., & Gui, L. (2025) · BMC Public Health · doi:10.1186/s12889-025-21923-0 · Cited by 9
“According to the diagnostic criteria published by the American Diabetes Association in 2024 [25], participants were defined as having a newly diagnosed diabetes when one of the following was present: (1) glycated hemoglobin A1c (HbA1c) ≥ 6.5%, (2) fasting blood glucose ≥ 126 mg/dL, or (3) random…”
InfluentialCaballero-María, P., Caballero-Villarraso, J., Arenas-Montes, J., Díaz-Cáceres, A., Castañeda-Nieto, S., Alcalá-Díaz, J. F., Delgado-Lista, J., Rodríguez-Cantalejo, F., Pérez-Martínez, P., López-Miranda, J., et al. (2025) · Applied Sciences · doi:10.3390/app15042228 · Cited by 7
Parlițeanu, O.-A., Bălteanu, M. A., Zaharia, D. C., Constantinescu, T., Cristea, A. M., Dumitrache‐Rujinski, S., Nica, A. E., Voineag, C., Alexe, O., Tabacu, E., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15050554 · Cited by 10
“Studying glycemic homeostasis in the context of SARS-CoV-2 infection is essential, given that the virus can affect pancreatic beta-cell function, leading to acute metabolic disturbances [2].”
Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 13
Mu, H., Zhang, Q., Huang, W., Pan‐Hammarström, Q., Zhang, Y., Lu, Y., Zhu, Z., Jiang, X., Wang, G., Zheng, M., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1584049 · Cited by 10
Ulene, S. R., Wang, S., Cook, J. R., McAuley, F. M., Wooster, M. E., Faheem, K. F., Varoli, A., McGuinness, J. E., Vasan, N., Trivedi, M. S., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07745-z · Cited by 8
“…were considered to have euglycemia if their baseline A1c was 5.7% (euglycemia group), prediabetes if their baseline A1c was 5.7–6.4% (pre-DM group), or diabetes if their baseline A1c was ≥ 6.5% and/or they had a clinical diagnosis of diabetes mellitus prior to study enrollment (DM group) [22].”
InfluentialBody Mass Index Changes and Femur Fracture Risk in Parkinson's Disease: National Cohort Study
Ahn, S., Lee, H. S., & Lee, J. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13860 · Cited by 7
“Although the precise mechanisms linking this progressive decline in BMI to fracture risk in PD remain incompletely understood, the association may be mediated by a combination of fall-related vulnerability [2, 3] and alterations in bone metabolism [30].”
Freitag, A. C., Koller, O. G., Menezes, V. M., Luft, V. C., & de Almeida, J. C. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.06.006 · Cited by 9
Wang, Z., Wang, X., Guo, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071061 · Cited by 7
“Type 2 diabetes mellitus (T2DM) is a disease characterized by non-autoimmune heterogeneous progressive pancreatic islet β -cell insulin underproduction [1], which often occurs in the presence of insulin resistance (IR) and the metabolic syndrome (MS) [2,3].”
González-Lleó, A. M., Brito‐Casillas, Y., Martín-Santana, V., Gil-Quintana, Y., Tugores, A., Scicali, R., Riaño, M., Hernández-Baraza, L., Jiménez‐Monzón, R., Girona, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02857-8 · Cited by 8
“On the basis of these results, glucose metabolism status was reclassified according to the 2024 American Diabetes Association (ADA) criteria [20], and surrogate markers of insulin resistance and beta-cell function were calculated.”
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.